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Abstract.
Background: Our previous array, the Comparative Genomic Hybridisation design (CGH-array) for nemaline myopathy
(NM), named the NM-CGH array, revealed pathogenic copy number variation (CNV) in the genes for nebulin (NEB) and
tropomyosin 3 (TPM3), as well as recurrent CNVs in the segmental duplication (SD), i.e. triplicate, region of NEB (TRI,
exons 82–89, 90–97, 98–105). In the light of this knowledge, we have designed and validated an extended CGH array, which
includes a selection of 187 genes known to cause neuromuscular disorders (NMDs).
Objective: Our aim was to develop a reliable method for CNV detection in genes related to neuromuscular disorders for
routine mutation detection and analysis, as a much-needed complement to sequencing methods.
Methods: We have developed a novel custom-made 4 × 180 k CGH array for the diagnostics of NMDs. It includes the same
tiled ultra-high density coverage of the 12 known or putative NM genes as our 8 × 60 k NM-CGH-array but also comprises
a selection of 175 additional genes associated with NMDs, including titin (TTN), at a high to very high coverage. The genes
were divided into three coverage groups according to known and potential pathogenicity in neuromuscular disorders.
Results: The array detected known and putative CNVs in all three gene coverage groups, including the repetitive regions of
NEB and TTN.
Conclusions: The targeted neuromuscular disorder 4 × 180 k array-CGH (NMD-CGH-array v1.0) design allows CNV
detection for a broader spectrum of neuromuscular disorders at a high resolution.
Keywords: Array comparative genomic hybridisation (aCGH), copy number variation (CNV), nebulin, NEB, titin, TTN,
NM-CGH, NMD-CGH
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INTRODUCTION
Congenital myopathies are hereditary disorders
within the heterogeneous group of neuromuscular
disorders (NMDs). They may be caused by mutations,
including copy number variations (CNVs), in genes
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coding for structural proteins of the sarcomere, genes
for membrane or matrix proteins, or genes affect-
ing muscular development by playing a role in e.g.
protein turnover or muscle differentiation [1]. The
wide array of causative genes and mutations leads
to a widely varying group of disorders; they may be
passed on according to all modes of inheritance and
they display a multitude of clinical phenotypes, with
variation in progression, severity and distribution of
muscle weakness [2, 3].
It is important to note that the phenotypes of con-
genital myopathies may overlap with each other and
with other neuromuscular disorders, and that differ-
ent mutations in the same gene may cause various
phenotypes, thus challenging diagnostics. Specifi-
cally designed follow-up and specific putative future
therapies can be administered only when the cor-
rect molecular diagnosis and the underlying causative
mechanisms of the disorder have been determined
[3, 4].
CNVs are structural changes of the genome, in
which a certain genomic sequence is present in the
studied genome at an aberrant copy number com-
pared with the reference genome. CNVs were initially
described as variations of at least 1 kb in size [5], but
modern technology has allowed CNV detection at a
higher resolution, and the minimum size for a deleted
or duplicated sequence has been suggested to be as
small as 50 bp [6]. Estimations are that de novo locus-
specific CNVs have a higher mutation rate compared
with nucleotide substitutions [5].
While thousands of regions are prone to benign
CNVs [7], variants that interfere with normal
gene expression or function can be potentially
pathogenic [8]. For example, Duchenne muscu-
lar dystrophy (DMD; MIM ID: DMD #310200)
is commonly caused by CNVs in the DMD gene
[9, 10]. Furthermore, pathogenic CNVs have been
shown to contribute to roughly 6.4% of nemaline
myopathy cases (NM; MIM IDs: NEM1 #609284,
NEM2 #256030, NEM3 #161800, NEM4#609285,
NEM5 #605355, NEM6 #609273, NEM7 #610687,
NEM8 #615348, NEM9 #615731, NEM10 #616165,
NEM11 #617336) [11].
Array Comparative Genomic Hybridisation
(aCGH) constitutes the standard method for research
and diagnostics into disorders with pathogenetic
mechanisms involving CNVs. Copy number vari-
ation analysis methods based on Next-Generation
Sequencing (NGS) are evolving [12], but the preci-
sion and reliability of aCGH remains to be matched
by computer algorithms.
Especially regions of segmental duplication (SD)
pose a challenge to NGS based CNV analysis
methods [13], and are in fact often excluded from
commercial CGH arrays and sequencing panels. Such
regions are found both in the nebulin gene (NEB)
[14] and the titin gene (TTN) [15], the products of
which are enormous sarcomeric proteins. In NEB, this
region holds a threefold repetition of an 8-exon block
(exons 82–89, 90–97 98–105), referred to as the trip-
licate region (TRI). The NEB TRI region is known
to harbour CNVs – gains and losses of one 8-exon
block are considered benign, while gains of more than
one 8-exon block are considered to be pathogenic
[16]. In TTN, the SD constitutes a threefold repetition
of 9 exons (exons 166–174, 175–183, and 184–192)
within the PEVK segment of the gene, followed by
fourth copies of the first two exons of the repeated
block [15]. CNVs in this type of region are all but
rare, and may potentially be pathogenic [16].
Here we describe our custom targeted neuromus-
cular disorder CGH array (NMD-CGH array v1.0),
targeting 187 different genes related to NMDs. As
NM can be caused by CNVs [11, 17, 18], especially
common in NEB, we hypothesised that CNVs may be
disease-causing also in other genes related to NMDs
– consequently, that there probably are undiscovered
pathogenic CNVs to be identified in these genes.
The array targets a wide variety of genes related
to NM and other NMDs. The design includes our
previously published, targeted 8 × 60 k nemaline
myopathy CGH-array (NM-CGH array) [11] in an
updated version. In addition to the 11 published
and one unpublished NM-causing gene; ACTA1,
NEB, TPM3, TPM2, TNNT1, CFL2, KBTBD13,
KLHL40, KLHL41, LMOD3, MYPN and YBX3, the
array includes 175 carefully chosen genes related to
other NMDs – amongst these, the TTN, dystrophin




Forty-six DNA samples from 19 different clini-
cians in 11 countries were acquired for the validation
of the array. The 46 DNA samples included 3 positive
controls with known CNVs, 9 blind cross-validation
samples, and 30 patient samples. In addition, we
acquired 4 healthy control samples, of which 3
from the Finnish Red Cross Blood Service and
one commercial reference sample (Male reference
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Table 1
The representative numbers of samples and families included in
the validation process
Samples Families
Healthy controls 4 4
Positive controls 3 3
Cross-validation samples 9 9
Patient samples, of which 30 20
First mutation previously identified 10 8
Candidate mutation previously identified 7 3
Both mutations unidentified 13 9
Altogether 46 36
DNA, Promega Corporation, Madison, WI, USA).
(Table 1).
The study was approved by the local Ethics Com-
mittees and samples were obtained according to the
Declaration of Helsinki of 1975.
Microarray design, protocol, and data analysis
The CGH array was designed with the support of
Oxford Gene Technology IP Limited Ltd (Oxford,
UK) (Human reference sequence, GRCh37/Hg19).
The array covers 187 genes associated with muscular
disorders, divided into 3 different categories of highly
targeted levels.
The array includes the known NM genes (ACTA1,
CFL2, KBTBD13, KLHL40, KLHL41, LMOD3,
NEB, TNNT1, TNNT3, TPM2, TPM3, MYPN) and
176 known or candidate neuromuscular disorder
genes, including those of the 1st version of the
targeted NGS MyoCap panel [19]. The current num-
ber of targeted probes chosen for the design is
150,300/180,000, leaving space for future additions
and updates.
The genes have been divided into three gene cov-
erage groups of varying coverage according to the
known and potential NMD-causing pathogenicity
harboured by the genes. Coverage group 1 includes
the NM genes at the same ultra-highly tiled cov-
erage as the previously validated and published
8 × 60 k NM-CGH array [11]. Coverage group 2
consists of 29 other characterised muscle disorder
genes (ANO5, BAG3, BIN1, CRYAB, DES, DNM2,
DYSF, FLNC, GNE, HSPB8, KLHL9, LDB3, MTM1,
MYBPC1, MYBPC2, MYH1, MYH13, MYH2, MYH3,
MYH4, MYH7, MYH8, MYOT, OBSCN, OBSL1,
RYR1, SEPN1, TIA1, TTN) at a very high coverage.
The remaining 147 genes (Supplementary Table 1) of
coverage group 3 were also targeted at a high level of
coverage, with approximately 4 probes covering each
exon. The coverage group 2 and 3 genes are either
known neuromuscular disorder genes or strong can-
didates for such. Of these, we selected genes coding
for structural proteins of the sarcomere to be targeted
at group 2 level as their putative impact on muscu-
lar structure is clearer than that of regulatory genes
such as transcription factors, which were targeted at
group 3 level. Exceptions to this rule are genes that are
known to harbour pathogenic or putative pathogenic
CNVs in group 2.
In all the groups, a minimum of one probe per exon
and per intron was targeted in each gene. Flanking
regions were included 25 kb upstream and down-
stream of the targeted genes. The coverage level of
the three gene groups is presented in Table 2.
In addition, the backbone coverage was increased
from approximately 1 probe per Mb to 1 probe per
300 kb, in order to allow for the detection of large
genomic rearrangements, as well as better alignment
throughout the genome. The 12,300 backbone probes
are spaced evenly across the non-targeted regions.
The USCS Genome Browser (https://genome.
ucsc.edu/) online application was used to visualise the
probe distribution in the designing process. All genes
were targeted at least at the exon level. In addition to
the Oxford Gene Technology in-house probes, new
custom probes were designed for the regions of inter-
est, especially in the regions of repetitive sequences.
Labelling, hybridisation, scanning and analysis of
the array was performed according to the manu-
facturer’s protocol (Oxford Gene Technology Ltd,
ISCA array, Cytosure Genomic DNA labelling kit
protocol, 4 × 180 k format, code 020020). We used
a commercial male DNA reference for all the stud-
ied samples (Promega Corporation). The array slides
were scanned using the Agilent DNA Microar-
ray Scanner G2505C with 2 m resolution, Agilent
Scan Control version A.8.5.1 (Agilent Technolo-
gies Inc, Santa Clara, CA, USA) and normalised
and further analysed in Feature Extraction software
v.12.0.0.7 (Agilent Technologies). The Cytosure
Software v.4.6.85 (Hg19) (Oxford Gene Technology
Ltd) was used for graphic analysis of the data. A min-
imum of 5 probes was used as a threshold for making
a positive call for an aberration. The array profiles
and aberration calls were also manually checked.
Validation
The initial validation of the NMD-CGH array
was made using 4 healthy controls and 3 positive
controls (identified with the NM-CGH array). In addi-
tion, we performed a blind cross-validation process
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with 9 samples. In these, CNVs had been detected
with 4 different NGS-based CNV detection algo-
rithms (CoNIFER v0.2.2, XHMM v1.1, ExomeDepth
v1.1.10 and CODEX v1.4.0). The CNV detection by
algorithms was performed as described in Välipakka
et al., 2017 [20].
Subsequently, we ran 30 patient samples from 20
families, which had not previously been analysed for
CNVs by any method.
RESULTS
The validation runs on the 7 control samples con-
firmed the coverage, specificity, and resolution of the
array and the quality of the probes chosen. In the 4
healthy controls (samples 9–12), we identified a gain
in the TTN SD region (coverage group 2) in 1 sam-
ple. In the 3 positive controls (samples 1-2 and 8),
we identified 1 one-copy loss in the NEB TRI region
(coverage group 1) and 3 losses in the TTN SD region,
as well as the known pathogenic changes in NEB
(coverage group 1) and DMD (coverage group 3).
In the blind cross-validation samples (16–23, 46),
we were able to detect the expected CNVs. The
changes include a partial duplication of the adjacent
coverage group 2 genes MYH6 and MYH7 (Fig. 1A)
and duplications in coverage group 3 genes MYOM
and PYGM (Fig. 1B-C). Moreover, deletions in the
genes TTN (Fig. 1D), DMD, LDHB, and the upstream
region of COL6A3 were detected (all but TTN belong
to coverage group 3). A supposedly benign gain
was detected in the TTN SD region of one sample
(Fig. 1F). The NGS-based analysis programmes had
flagged one change that was not detected on the array
and was concluded to be a false positive. The cross-
validation process confirmed the ability of the array
to detect CNVs in all gene coverage groups.
Table 2
The coverage of exon, intron and flanking regions in the three subgroups
Coverage by gene coverage group
Group 1 Group 2 Group 3
Exon 10 bp tiling, +/– Adjacent probes, +/– ∼4 probes/exon
Intron 20 bp tiling, +/– Adjacent probes, +/– ∼1–3 probes/intron
Flanking ±25 kb ±25 kb ±25 kb
+/– signifies probe targeting on both the forward and the reverse strand. ± signifies the region
covered both upstream and downstream of the targeted genes.
Fig. 1. A demonstration of the array results. NEB is targeted at Coverage group 1 level, TTN and MYH7 are targeted at Coverage group 2
level and MYOM1 and PYGM are targeted at Coverage group 3 level.
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Table 3
The prevalence of gains and losses in the NEB triplicate region
(TRI) and TTN segmental duplication (SD) region in the different
sample categories.
Positive Healthy Patients and Total
controls controls blind validation
samples
NEB TRI gain 0 0 1 1
NEB TRI loss 0 0 1 1
TTN SD gain 0 1 6 7
TTN SD loss 3 0 3 6
The diagnostic runs performed on patient samples
(samples 3–7, 13–15, 24–45) revealed two aberra-
tions of unknown significance in coverage group
2 genes, one upstream deletion of ANO5 and one
upstream duplication of OBSL1 partially covering
the gene DNPEP. Benign variation of the NEB TRI
region was detected in 2 samples altogether, an exam-
ple of which is presented in Fig. 1E. Copy number
variation in the TTN SD region was seen in 8 diag-
nostic samples, of which 3 were losses and 5 were
gains.
In addition to the known and putative pathogenic
aberrations and known benign variations detected,
the novel NMD-CGH array revealed previously
unrecorded variation in the TTN SD region (Table 3).
Variation in the TTN SD region was seen in 13 sam-
ples altogether. These findings warrant further studies
and will be the subject of another publication.
All changes identified, including the controls and
cross-validation samples, are presented in Table 4.
To date, we have run around 410 samples from
approximately 300 families with NM or related dis-
orders using the NM-CGH or NMD-CGH-array. The
yield of pathogenic CNVs in these samples has been
altogether around 13%, of which 4.5% are pathogenic
CNVs within the NEB TRI region.
DISCUSSION
The design of the novel NMD-CGH array allows
us to reliably identify CNVs in genes associated with
muscle disorders, on a resolution varying from circa
70 bp (unpublished data) to the exon level, depend-
ing on the gene coverage group. The design can and
will be updated based on new findings: we can move
genes to a higher-tiled coverage group, or add alto-
gether new genes to the array. Any recurrent, unclear
or putatively pathogenic variation identified on our
array or by a different method can be basis enough to
move a gene to the higher coverage group. It is thus a
dynamic method for the research and diagnostics of
CNVs in genes causing neuromuscular disorders.
The human genome harbours more than 1000
regions prone to benign variation in terms of copy
number, and CNVs have already been proven to con-
stitute part of the mutation spectra behind muscle
disorders, e.g. NM [1, 17, 18]. In patients lack-
ing a molecular diagnosis for their disorders or in
whom only one recessive mutation has been iden-
tified, the NMD-CGH array allows for precise and
reliable detection of deletions and duplications in a
wide range of NMD genes and NMD candidate genes.
The genes were carefully picked out and divided into
the coverage groups based on the current knowledge
of proven and putative NMD genes, and the resolution
at which these genes and their CNVs can be detected
on the array.
Despite advancements in NGS data analysis of
CNVs, aCGH still remains the gold standard method
for CNV detection and analysis, especially in diag-
nostics, due to the method being well-established
and reliable, and its quick sample turnover time. The
repetitive nature of the SD regions in certain genes,
e.g. NEB and TTN, present challenges for analysis by
conventional NGS methods. Algorithms can predict
CNVs, but whole-exome, targeted exome, or whole-
genome data are not as clear, precise and sensitive
as a well-designed CGH array. The number of false
positives and false negatives is higher, and the find-
ings still require validation by other methods, such
as aCGH. Repetitive regions may harbour CNVs in
unconventional numbers [16], with the baseline devi-
ating from the normal diploid copy number of two,
and these can be difficult to determine using NGS-
based methods and read counts only. In addition,
the CNV breakpoints may be pinpointed with higher
precision using a densely tiled aCGH design com-
pared with sequence-based methods. However, for
determining exact breakpoints at the base-pair level,
Sanger sequencing is still the only reliable method.
Our array allows for the detection of CNVs, not
only in NMD genes in general, but also in the repeti-
tive NEB TRI region [16], and the SD region of TTN.
These regions are typically excluded from commer-
cial CGH-array designs because of the difficulty their
repetitive nature imposes on the analysis. In terms of
the NEB TRI region, our array has been validated
[16], and we are currently validating the analysis of
the SD region of TTN.
Based on our results so far, we expect the yield of
pathogenic CNVs to be similar in range (∼13%) as



















Copy number variations identified on the NMD-CGH-array during the validation process and the subsequent diagnostic runs
Sample ID Gene Variation Size Coverage group
1 DMD partial deletion ChrX.hg19:g.(32,551,900 32,563,471) (32,953,942 32,978,285)del 390,471–466,385 bp 3
1, 2, 8, 13 TTN SD loss Chr2.hg19:g.(179,516,753 179,517,001) (179,528,302 179,528,842)del 11,301–12,089 bp 2
5, 9, 19, 25 TTN SD gain Chr2.hg19:g.(179,516,799 179,517,346) (179,528,170 179,529,256)dup 10,824–12,457 bp 2
29 NEB TRI loss Chr2.hg19:g.(152,433,608 152,434,494) (152,464,242 152,464,694)del 29,748–31,086 bp 1
25 NEB TRI gain Chr2.hg19:g.(152,433,608 152,434,494) (152,466,075 152,466,085)dup 31,581–32,477 bp 1
3, 38 OBSL1 upstream duplication Chr2.hg19:g.(220,438,234 220,439,293) (220,460,509 220,569,618)dup 21,216–131,384 bp 2
8 NEB partial deletion Chr2.hg19:g.(152,434,836 152,435,622) (152,554,712 152,561,404)del 109,090–126,568 bp 1
15 [20] TTN partial deletion Chr2.hg19:g.(179,630,403 179,630,386) (179,636,145 179,636,177)del 5,754–5,774 bp 2
16 LDBH partial deletion Chr12.hg9:g.(21,803,624 21,806,090) (21,811,051 21,812,528)del 4,961–8,904 bp 3
17 DMD partial deletion ChrX.hg19:g.(30,843,289 31,086,990) (31,313,100 31,327,408)del 226,110–484,119 bp 3
18 MYOM1 partial duplication Chr18.hg19:g.(3,155,151 3,155,985) (3,653,512 3,815,684)dup 497,527–660,533 bp 3
20 PYGM duplication Chr11.hg19:g.(64,155,908 64,440,343) (64,553,037 64,758,928)dup 112,694–603,020 bp 3
21 MYH6+MYH7 partial duplication Chr14.hg19:g.(23,859,986 23,859,988) (23,889,063 23,889,443)dup 29,075–29,457 bp 2
36 ANO5 upstream deletion Chr11.hg19:g.(21,579,750 21,931,190) (22,207,427 22,208,122)del 276,237–628,372 bp 2
46 COL6A3 upstream deletion Chr2.hg19:g.(238,318,105 238,322,413) (238,346,871 238,440,079)dup 23,458–121,974 bp 3
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CONCLUSIONS AND FUTURE
PROSPECTS
The NMD-CGH-array constitutes a dependable
CNV analysis method for the diagnostics of NMDs.
The use of the NMD-CGH array will continue in our
laboratory as a first tier diagnostic tool for patients
and families whose disease-causing variants remain
unidentified.
The recurrent CNV in the SD region of TTN will be
the topic of a further project. Preliminary data suggest
that the region is highly prone to variation in a similar
fashion as the NEB TRI region. It is possible that this
region, too, will be found in some patients to contain
modifying or pathogenic CNVs.
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[16] Kiiski K, Lehtokari V-L, Löytynoja A, Ahlstén L, Laitila
J, Wallgren-Pettersson C, et al. A recurrent copy num-
ber variation of the NEB triplicate region: Only revealed
by the targeted nemaline myopathy CGH array. Euro-
pean Journal of Human Genetics. 2016;24(4):7. doi:
10.1038/ejhg.2015.166
[17] Anderson SL, Ekstein J, Donnelly MC, Keefe EM, Toto NR,
LeVoci LA, et al. Nemaline myopathy in the Ashkenazi Jew-
ish population is caused by a deletion in the nebulin gene.
Hum Genet. 2004;115(3):185-90. doi: 10.1007/s00439-
004-1140-8
[18] Lehtokari VL, Greenleaf RS, DeChene ET, Kellinsalmi M,
Pelin K, Laing NG, et al. The exon 55 deletion in the neb-
ulin gene–one single founder mutation with world-wide
occurrence. Neuromuscul Disord. 2009;19(3):179-81. doi:
10.1016/j.nmd.2008.12.001
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